… for the erlotinib group and 11·5 months for the placebo group, median PFS was significantly
longer with erlotinib than with placebo: 12·3 weeks for patients in the erlotinib group versus …

… Our phase 3 results confirm these early findings. Furthermore, retrospective analyses of
two phase 3 NSCLC trials show a positive correlation between rash and treatment effect on …

… Epidermal growth factor receptor (EGFR) –tyrosine kinase inhibitors have proven efficacy
in advanced non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib would be …

… To the best of our knowledge, the present study was the first head-to-head phase III
randomised controlled trial comparing erlotinib with gefitinib in EGFR activating mutation-positive …

… in lung cancer tumorigenesis. We compared the efficacy of cabozantinib alone or in combination
with erlotinib versus erlotinib … Randomized phase III trial of erlotinib versus docetaxel as …

… for first-line erlotinib versus chemotherapy in … erlotinib was also reported in the Chinese,
phase III, first-line OPTIMAL study [10]. Additionally, the single-arm, first-line, Japanese, phase …

… that of erlotinib. Here we report the results of a phase III, randomized, placebo-controlled
trial (Tarceva Lung Cancer Investigation [TALENT]) of cisplatin and gemcitabine with or without …

… A phase 3 clinical trial compared erlotinib alone with erlotinib plus bevacizumab in patients
who had disease progression after platinum-based therapy. In that trial, patients were not …

8006 Background: E and D are standard cares for previously treated patients with advanced
NSCLC. Although E shows significant clinical benefits over best supportive care in the …

… To our knowledge, the EURTAC is the first phase 3 study to show that erlotinib can improve
median progression-free survival in European patients (who were predominantly white) with …